This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biogen's MS Pill Wins Again

Updated with analyst reaction.

WESTON, Mass. ( TheStreet) -- Efficacy of Biogen Idec's (BIIB - Get Report) experimental multiple sclerosis pill BG-12 was confirmed and demonstrated superiority over Teva's (TEVA - Get Report) currently marketed Copaxone, according to a second, successful late-stage study released Wednesday.

Biogen Idec plans to seek regulatory approval for BG-12 based on the positive data from the two, phase III studies, the first of which was announced in April. If approved, BG-12 will be Biogen's first oral MS drug therapy and another potential blockbuster, grabbing market share from both existing injectable drugs as well as competing oral therapies, analysts predict.

Biogen shares were up $10.83, or 10%, to $117.70 in early Wednesday trading.

"Overall, on a scale of 1-10, with '10' being absolute best case, we would put these data at, perhaps 8 or 9," said ISI Group biotech analyst Mark Schoenebaum, in an email to clients Wednesday morning.

"Our take is that BG-12 clearly showed a numerical difference against Copaxone (both were compared against placebo)... We see this as a major positive for the stock," said Deutsche Bank biotech analyst Robyn Karnauskas in an email to clients. BG-12's peak sales could reach $3-4 billion, making Biogen shares worth $129-$136, she said.

In the phase III study known as "Confirm" released Wednesday, treatment with BG-12 twice daily reduced the annualized relapse rate by 44% compared to placebo after two years. A three-times daily dose of BG-12 reduced the annualized relapse rate by 51% compared to placebo after two years. Both results were statistically significant, achieving the primary endpoint of the study.

The "Confirm" study also enrolled MS patients treated with Teva's injectable Copaxone as a comparator. The reduction in the annualized relapse rate for these patients was 29% compared to placebo after two years.

BG-12 reduced disability progression by 21% at the twice-daily dose and 24% at the three-times daily dose compared to placebo, while Teva's Copaxone reduced disability progression by 7% versus placebo. These results were not statistically significant, however, owing to an unexpectedly low rate of disease progression among patients treated with a placebo, Biogen said.

Biogen currently sells two injectable drugs for multiple sclerosis -- Avonex and Tysabri, the latter of which is co-marketed by Elan (ELN).

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
BIIB $281.08 0.00%
TEVA $54.99 0.00%
AAPL $95.03 0.21%
FB $116.73 0.00%
GOOG $691.02 0.00%


Chart of I:DJI
DOW 17,830.76 -210.79 -1.17%
S&P 500 2,075.81 -19.34 -0.92%
NASDAQ 4,805.2910 -57.85 -1.19%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs